Peptide Acronyms Decoded: BPC, TB, GHK-Cu, CJC

Peptide names look like license plates: BPC-157, TB-500, GHK-Cu, CJC-1295, GHRP-6. The letters feel like they should mean something specific — a benefit, a mechanism, a promise — but most of the time they don’t. An acronym usually just records where the molecule came from, who made it, or which hormone pathway it borrows from. It says nothing about whether the thing works, whether it’s safe, or whether it’s legal to put in your body. This is a decoder for the most common abbreviations, so you can read a label without mistaking a naming convention for a claim. If you want the same definitions in searchable form, our peptide research glossary collects this peptide acronyms list alongside the rest of the vocabulary.

The two kinds of peptide acronyms

Before the letters, one distinction does most of the work. Peptide abbreviations fall into two buckets:

• Identity or origin codes — the letters point to a source protein, a discoverer, or a company. Examples: BPC, CJC, PT-141. These tell you nothing about mechanism.
• Function or pathway labels — the letters describe the hormone system the molecule acts on. Examples: GHRP, GHRH, GHS, GLP-1, GIP. These tell you the pathway, but still not the strength of the evidence.

Once you know which bucket an acronym is in, you know how much to read into it. A “Growth Hormone-Releasing Peptide” at least advertises what pathway it targets. “BPC” advertises nothing except a hopeful name a lab gave a fragment in the 1990s.

The big four, decoded

BPC — Body Protection Compound. BPC-157 is a 15-amino-acid peptide (a pentadecapeptide), sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, first described by Sikiric and colleagues in 1993 as a fragment of a protein in human gastric juice. “Body Protection Compound” was the name researchers gave that parent protein’s protective activity — it’s an aspirational description, not a demonstrated outcome. What is sold is made by solid-phase synthesis, and the 2025 literature review notes the sequence shares no homology with known intestinal peptides. It has not been approved for medical use by the FDA or any other national regulator, and the U.S. Anti-Doping Agency lists it as prohibited at all times under category S0 (non-approved substances) — it was added to the WADA list by name in 2022, the first substance ever named as an example in that section.

TB — Thymosin Beta. TB-500 is a synthetic fragment corresponding to the actin-binding region of thymosin beta-4, a naturally occurring signaling protein; that region is the seven residues LKKTETQ, positions 17–23 of the parent molecule. So “TB” is a straight abbreviation of the parent molecule’s name. Note the important gap: the research-chemical “TB-500” is a short synthetic fragment, not the full-length thymosin beta-4 that has been studied more formally in clinical settings.

GHK-Cu — Glycyl-Histidyl-Lysine + copper. This one is refreshingly literal. GHK is the three-letter shorthand for the tripeptide made of glycine (G), histidine (H), and lysine (K — the single-letter code for lysine). “Cu” is the chemical symbol for copper. So GHK-Cu is simply the glycyl-L-histidyl-L-lysine peptide bound to a copper ion, which it binds with high affinity. Pickart’s group dates the discovery to 1973, when GHK was identified as an activity in human albumin that made old human liver tissue synthesize proteins like younger tissue. We cover what it does and doesn’t do in the companion piece on GHK-Cu, the copper peptide behind the skin claims.

CJC — ConjuChem. Unlike the others, CJC isn’t chemistry at all — it’s a corporate code. CJC-1295 is a long-acting analog of growth hormone-releasing hormone; the trial of it registered on ClinicalTrials.gov lists ConjuChem, a Canadian biotech, as sponsor, and the “CJC” reflects that developer’s naming scheme. When you see “CJC-1295 DAC,” the DAC stands for Drug Affinity Complex — ConjuChem’s albumin-binding technology, in which a reactive chemical group is built onto the peptide so that it couples to circulating albumin and inherits albumin’s slow clearance. In the published human study, the estimated half-life of CJC-1295 was 5.8 to 8.1 days.

A wider acronym table

Beyond the big four, a handful of function-based abbreviations recur constantly. These describe hormone pathways, which is why the same letters appear across many different molecules.

Acronym	Stands for	What it actually names
BPC	Body Protection Compound	An aspirational name for a gastric-juice-derived fragment (BPC-157)
TB	Thymosin Beta	The parent protein of the TB-500 fragment
GHK-Cu	Glycyl-Histidyl-Lysine + Cu (copper)	A copper-bound tripeptide
CJC	ConjuChem	The developer that coined the code
DAC	Drug Affinity Complex	A half-life-extending albumin-binding add-on
GHRP	Growth Hormone-Releasing Peptide	A family of synthetic secretagogues (GHRP-2, GHRP-6)
GHRH / GRF	Growth Hormone-Releasing Hormone / Factor	The natural hypothalamic hormone (and analogs like sermorelin)
GHS	Growth Hormone Secretagogue	Any compound that prompts the pituitary to release GH
GLP-1	Glucagon-Like Peptide-1	The incretin hormone behind semaglutide-class drugs
GIP	Glucose-dependent Insulinotropic Polypeptide	The second incretin, targeted by tirzepatide
PT-141	Palatin Technologies code	The developer code for bremelanotide

A quick note on that last row: PT-141 (bremelanotide) is, in the words of its own FDA label, “a melanocortin receptor (MCR) agonist that nonselectively activates several receptor subtypes,” and unlike most items here it was actually approved — NDA 210557, cleared 21 June 2019 as Vyleesi, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Palatin Technologies, the company behind the “PT” code, sponsored the trials. It’s a good reminder that approval status varies wildly and has nothing to do with how the acronym reads.

Why “GHRP” and “GLP-1” are the useful ones

If an acronym encodes a pathway, it carries real information. GHRP (Growth Hormone-Releasing Peptide) and GHS (Growth Hormone Secretagogue) both tell you the compound is trying to nudge your pituitary into releasing more growth hormone. A 2026 review of this class puts the mechanism plainly: GHRPs are “short synthetic peptides that stimulate endogenous GH secretion by activating the ghrelin receptor — the growth hormone secretagogue receptor type 1a (GHSR-1a).” GHRH compounds mimic the natural releasing hormone instead; sermorelin is GHRH(1–29), and tesamorelin is the one GHRH analog with a live FDA approval, for excess abdominal fat in adults with HIV-associated lipodystrophy. GLP-1 and GIP name the two incretin hormones that regulate insulin and appetite; tirzepatide’s label describes the drug as a “glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist,” which is the acronym doing exactly the work it should.

That’s the payoff of decoding: a function label narrows down what system is involved. It still doesn’t tell you the dose, the evidence quality, or the risk — and for research peptides, that evidence is usually thin.

The honest caveat

Decoding an acronym is vocabulary, not validation. Most of the peptides above are sold as “research chemicals,” are not approved for human use, and have little or no controlled human data behind the marketing. BPC-157 in particular has been flagged by the U.S. Department of Defense’s Operation Supplement Safety as a prohibited, unapproved drug turning up in wellness products. Knowing that “BPC” means “Body Protection Compound” doesn’t make the compound protective, approved, or safe.

Treat this list as a reading aid. When you see a new abbreviation, ask which bucket it’s in — origin code or pathway label — and then go find the actual evidence separately. For a worked example of that gap between name and data, see BPC-157: evidence vs hype, and keep the full peptide research glossary handy for the terms this piece didn’t cover. This is educational information about nomenclature, not medical advice — consult a qualified clinician before acting on anything in this space.

Sources

Definitions above are drawn from the linked reference pages. PT-141/bremelanotide’s developer origin (Palatin Technologies) and approval history, and the sermorelin/tesamorelin GHRH-analog framing, are from their respective Wikipedia entries.